Trial of the Week: REDUCE

ACC 2024 Rapid Reaction: Part II Special Guest: Snehal Bhatt, PharmD, BCPS, FASHP, AACC @SnayCardsPharmD   04:05 – EMPACT-MI 29:35 – ULTIMATE-DAPT   Reference List: https://pharmacytodose.files.wordpress.com/2024/05/acc-2024-part-ii-references.pdf   PharmacyToDose.Com @PharmacyToDose [email protected] Learn more about your ad choices. Visit megaphone.fm/adchoices

ACC 2024 Rapid Reaction: Part I Special Guest: Ryan Caputo, PharmD, BCCP @RyanCaputo1   04:05 – DanGer Shock 29:15 – REDUCE-AMI   Reference List: https://pharmacytodose.files.wordpress.com/2024/05/acc-2024-part-i-references-1.pdf   PharmacyToDose.Com @PharmacyToDose [email protected] Learn more about your ad choices. Visit megaphone.fm/adchoices

Rapid Sequence Intubation (RSI): Part II Special Guest: Christine Groth, PharmD, FCCM, BCCCP @GrothChristine Angela Slampak-Cindric, PharmD, BCPS, BCCCP, FCCM @AngelaSlampak Kevin Kaucher, PharmD, BCCCP   04:05 – Guideline development/involvement 12:50 – 2024 guideline overview 25:10 – Pharmacotherapy recommendations/considerations 42:40 – Non-pharmacologic recommendations/guideline insights 70:30 – Research ideas/conclusions   Reference List: https://pharmacytodose.files.wordpress.com/2024/05/rsi-part-ii-references.pdf   PharmacyToDose.Com @PharmacyToDose [email protected] Learn more about your ad choices. Visit megaphone.fm/adchoices

Trial of the Week: ESETT Special Guest: Ashley McCormick, PharmD, BCPS, BCCCP   Ashley McCormick joins to discuss the April Trial of the Week “Randomized Trial of Three Anticonvulsant Medications for Status Epilepticus” the ESETT study, published in NEJM in 2019. We set the scene by reviewing ASM PK/PD properties and discussing if there was a standard of care first-line treatment. Then we do a deep dive into the ESETT trial of the week. Did the 75kg dose cap influence results? How appropriate was the BZD dosing? How does this % of seizure cessation compare to other studies? Where did this dosing scheme come from? Trial fun facts, medication safety considerations, and much, much more. Reference list: https://pharmacytodose.files.wordpress.com/2024/04/esett-trial-of-the-week-references.pdf   PharmacyToDose.Com @PharmacyToDose [email protected] Learn more about your ad choices. Visit megaphone.fm/adchoices

Thrombolytic Dosing in PE: Versus Series Special Guest: Lauren Igneri, PharmD, BCPS, BCCCP, FCCM   05:20 – High-risk PE 23:00 – Intermediate-risk 37:10 – Cardiac arrest 52:30 – Closing arguments 57:15 – Bonus: TNK v. tPA   Reference List: https://pharmacytodose.files.wordpress.com/2024/04/thrombolytic-dosing-in-pe-references.pdf   PharmacyToDose.Com @PharmacyToDose [email protected] Learn more about your ad choices. Visit megaphone.fm/adchoices

Trial of the Week: SEPSISPAM Special Guest: Katherine Spezzano, PharmD, MBA, BCCCP @KatSpazPharmD   Katherine Spezzano joins to discuss the April Trial of the Week “High versus Low Blood-Pressure Target in Patients with Septic Shock” the SEPSISPAM study, published in NEJM in 2014. We set the scene by reviewing the concept of autoregulation, guideline recommendations, and pre-SEPSISPAM research assessing BP goals in sepsis. Then we do a deep dive into the SEPSISPAM trial of the week. Would we see these same results with other vasopressors? Did each group meet their BP goal range? How do we balance AKI prevention and longer ICU LOS? What do our guidelines recommend now? Trial fun facts, alternate trial acronym ideas, and much more!   Reference list: https://pharmacytodose.files.wordpress.com/2024/04/sepsispam-trial-of-the-week-references.pdf   PharmacyToDose.Com @PharmacyToDose [email protected] Learn more about your ad choices. Visit megaphone.fm/adchoices

Glycemic Control in the Critically Ill: Part II Special Guests: Judi Jacobi, PharmD, FCCP, MCCM, BCCCP @JudiJacobi Michael Sirimaturos, PharmD, BCNSP, BCCCP, FCCM @MSirimaturos   04:10 – Becoming panel members 11:50 – Guideline scope and PICO questions 21:35 – 2012 v. 2024 guidelines 28:05 – Effect of TGC-FAST 30:40 – 2024 guideline deep-dive 42:00 – Clinical decision support tools 50:00 – Pediatric recommendations 54:40 – Important future research topics 66:05 – Guideline manuscript writing 76:10 – Take-home points   Reference List: https://pharmacytodose.files.wordpress.com/2024/04/glycemic-control-in-the-icu-part-ii-references.pdf   PharmacyToDose.Com @PharmacyToDose [email protected] Learn more about your ad choices. Visit megaphone.fm/adchoices

Literature Review Series November 2023 Special Guests: Arjay Mendoza, PharmD, BCPS, AAHIVP Brock Townsend, PharmD @Townsend_PharmD   04:30 – Featured Articles 35:25 – Cardiology 48:05 – Precision-based medicine potpourri 58:50 – Infectious Diseases 69:10 – PharmD   Reference List: https://pharmacytodose.files.wordpress.com/2024/04/november-lrs-2023-references.pdf   PharmacyToDose.Com @PharmacyToDose [email protected] Learn more about your ad choices. Visit megaphone.fm/adchoices

Trial of the Week: SOAP II Special Guest: Jessica Casey, PharmD, BCPS, BCCP @jmc_cardspharmd   Jessica Casey joins to discuss the April Trial of the Week “Comparison of Dopamine and Norepinephrine in the Treatment of Shock,” the SOAP II study, published in NEJM in 2010. We set the scene by reviewing catecholamine vasopressor receptor physiology, guideline recommendations, and pre-SOAP II research. Then we do a deep dive into the SOAP II trial of the week. Did including all forms of shock help or hurt? How does the mortality in this study compare with others? Would this have been as positive of a study in 2024? What do the guidelines recommend now? Is dopamine dead? Will anyone take norepinephrine’s throne? Jessica and I review trial fun facts, stand-out supplementary materials, and much, much more.   Reference list: https://pharmacytodose.files.wordpress.com/2024/04/soap-ii-trial-of-the-week-references.pdf   PharmacyToDose.Com @PharmacyToDose [email protected] Learn more about your ad choices. Visit megaphone.fm/adchoices

Trials of the Week: Landmark Nimodipine Studies Special Guest: Salia Farrokh, PharmD, BCCCP, FNCS @salia_farrokh   Salia Farrokh joins to highlight two landmark studies with nimodipine, “Cerebral Arterial Spasm – A Controlled Trial of Nimodipine in Patients with Subarachnoid Hemorrhage” published in NEJM in 1983 and “Effect of Oral Nimodipine on Cerebral Infarction and Outcome after Subarachnoid Hemorrhage: British Aneurysm Nimodipine Trial” published in 1989 in BMJ. We review aSAH treatments in the 1970’s and 1980’s and what evidence existed for nimodipine use before highlighting our two trials of the week. How does the study methodology compare from then to now? Where did our nimodipine dosing regimen come from? Is the term cerebral artery vasospasm out of date? Is it still appropriate to use evidence from the 1980’s in the 2020’s? Is there more to research with respect to nimodipine? What to do with missed nimodipine doses? We do a deep dive into all things nimodipine for aSAH, discussing the above and much more.   Reference list:  https://pharmacytodose.files.wordpress.com/2024/04/nimodipine-trial-of-the-week-references.pdf   PharmacyToDose.Com @PharmacyToDose [email protected] Learn more about your ad choices. Visit megaphone.fm/adchoices